Answers are grounded in this paper and cite their sources.
Among outpatients aged ≥60 years with COVID-19 in an Omicron-dominated era, treatment with nirmatrelvir-ritonavir was associated with a lower risk of hospitalization and all-cause death within 28 days, albeit with wide CIs and high numbers needed to treat. This finding was not observed in molnupiravir users and younger nirmatrelvir-ritonavir users.
No takes yet. Share an insight, caveat, or question.
Jorda et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: